TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00936689

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Selective TACE via microsphere loaded with Doxorubicin
Description: Chemoembolization with microspheres: doxorubicin (maximum dose of 75 mg x vials of microspheres) loaded with non-reabsorbable microspheres (sulfate hydrospheres) at the dose of 2 ml per vial (definitive embolization).

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Selective traditional TACE
Description: Traditional chemoembolization: epirubicin (maximum dose of 75 mg) conjugated with Lipiodol at the maximum dose of 15 ml + Spongel.
Study: NCT03567317

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP withdrawal
Description: Patients randomized to withdrawal will stop CPAP use for one week before study evaluations. Patients will also undergo a polysomnography to confirm the presence of severe OSA.
Study: NCT00910299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: One time 60 milligram (mg) oral loading dose and 10 mg once daily oral maintenance dose up to 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 75 mg oral daily maintenance dose up to 6 months.
Study: NCT02395172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Participants received 10 milligrams per kilogram (mg/kg) of avelumab as a 1-hour intravenous infusion once every 2 weeks until confirmed disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or Investigational Medicinal Product (IMP) as defined in the study protocol was fulfilled.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Participants received 75 mg per square meter (m\^2) (per label) of docetaxel by intravenous infusion once every 3 weeks until confirmed disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or Investigational Medicinal Product (IMP) as defined in the study protocol was fulfilled.
Study: NCT01911910

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic coaching plus standard care
Description: The HAPPY London web-based tool will provide the participant with an individualised score for their lifestyle and 10 year CV risk score, based mainly on the modified Framingham score, and provide tailored advice and education on the suboptimal factors. Ideal targets will be set and the information will be updated at 3 and 6 months allowing the participant to view their progress. Weekly emails with brief health and lifestyle advice will be sent to encourage healthier behaviour based on clinical studies or topical issues in the media. Links to social networks, such as Facebook posting and the ability to allow chosen family and friends to view their progress will aim to further encourage healthier behaviour.
Study: NCT05037435

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: The pentavalent rotavirus vaccine (live attenuated oral, freeze-dried)
Description: Group 1 (20 participants) - received the pentavalent live vaccine to prevent rotavirus infection Single-use orally 2.5 ml (1 dose).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Group 2 (20 participants ) - received placebo orally once of 2.5 ml (1 dose).
Study: NCT03704636

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVSENSOR00028
Description: Noninvasive pulse oximeter sensor
Study: NCT00313781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-751,871
Description: CP-750,871 is administered intravenously at a dose of 20 mg/kg on day 1 of each 21-day cycle (for patient convenience and logistical management, the dose of CP-751,871 may be deferred up to 7 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Docetaxel is administered IV on day 1 of each 21-day cycle, at a dose of 75 mg/m2.
Study: NCT04009928

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active stimulation of the medial forebrain bundle or subcallosal cingulate
Description: Deep brain stimulation of the medial forebrain bundle or subcallosal cingulate

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Active stimulation of the medial forebrain bundle or subcallosal cingulate
Description: Deep brain stimulation of the medial forebrain bundle or subcallosal cingulate

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham stimulation
Description: Sham stimulation for 2 weeks (Cross-over design)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Sham stimulation for 2 weeks (Cross-over design)
Study: NCT00849667

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Farletuzumab
Description: Farletuzumab IV infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Farletuzumab
Description: Farletuzumab IV infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin IV infusion.
Study: NCT00849667

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin IV infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin IV infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxane
Description: Taxane (Paclitaxel or Docetaxel) IV infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxane
Description: Taxane (Paclitaxel or Docetaxel) IV infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Taxane
Description: Taxane (Paclitaxel or Docetaxel) IV infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Farletuzumab-matched placebo
Description: Farletuzumab-matched placebo IV infusion.
Study: NCT01629407

Intervention type: OTHER
Intervention: Standard of Care
Description: Patients with glaucoma treated with standard of care at the discretion of the physician. There is no specific treatment required for this study.
Study: NCT02451787

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 2400 units per day for 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Description: 2400 units per day for 3 months
Study: NCT01334398

Intervention type: BEHAVIORAL
Intervention: Health & Wellness
Description: The specific content of the intervention was adapted from four existing evidence-based interventions: (1) Healthy Lifestyles for People with Disabilities, (2) Promoting Wellness for Women with MS, (3) Living Well with Disability, and (4) Social Skills and TBI: A Workbook for Group Treatment.

Intervention type: BEHAVIORAL
Intervention: Health & Wellness
Description: The specific content of the intervention was adapted from four existing evidence-based interventions: (1) Healthy Lifestyles for People with Disabilities, (2) Promoting Wellness for Women with MS, (3) Living Well with Disability, and (4) Social Skills and TBI: A Workbook for Group Treatment.
Study: NCT03153839

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aquatic physical activity in babies
Description: A programme based on four different types exercises realized in a swimming pool for twelve months.~Before the beginning of the aquatic physical activity, the infants will be evaluated. Afther that, the study group will practise the exercises with their parents in 20 minutes sessions twice a week and when they finish the programme they will be evaluated again.
Study: NCT03981159

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical training
Description: Physical training for three months, twice per week (60 minutes per session).
Study: NCT02492633

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: The Standard Intervention will be offered to residents at all of Beacon Communities properties, regardless of the presence of this study. The standard intervention will be implemented as part of the smoke-free initiative roll out and will consist of: monthly articles in newsletters, re-usable shopping bag giveaways touting cessation messages, information provided via the property websites, and training of Residential Service Coordinators (RSCs) using the 8-session smoking cessation group training provided by the American Lung Association. The RSCs will offer group cessation counseling sessions for residents who would like support to quit smoking.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The Standard Intervention will be offered to residents at all of Beacon Communities properties, regardless of the presence of this study. The standard intervention will be implemented as part of the smoke-free initiative roll out and will consist of: monthly articles in newsletters, re-usable shopping bag giveaways touting cessation messages, information provided via the property websites, and training of Residential Service Coordinators (RSCs) using the 8-session smoking cessation group training provided by the American Lung Association. The RSCs will offer group cessation counseling sessions for residents who would like support to quit smoking.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: At a subset of 6 Beacon Communities properties, residents will receive an 'enhanced intervention' in addition to the 'standard intervention' that Beacon Communities is already providing. The enhanced intervention will consist of the following:~1. A web-based smoking cessation intervention via Facebook~2. Enhanced gain-framed messaging communicated via several channels. Gain framed messages will incorporate themes of smoking cessation and policies which aim to distinguish from the vast 'library' of traditional messages which focus on loss-framing.~3. A behavioral nudge designed to enhance public support for the smoke free policy, through personal adoption and adherence to the policy. This will be done by promoting a publicly viewable pledge program.
Study: NCT03026348

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Phosphate Buffer

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Phosphate Buffer
Study: NCT00313781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Prednisone is administered at a dose of 5 mg twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: Docetaxel is administered IV on day 1 of each 21-day cycle, at a dose of 75 mg/m2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: Prednisone is administered at a dose of 5 mg twice daily.
Study: NCT02767297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDL169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDL169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDL169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDL169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDL169
Study: NCT03877640

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BTL EMSELLA
Description: High intensity focused electromagnetic (HIFEM) technology induces deep pelvic floor muscle contractions designed to deliver the equivalent of 11,200 Kegel exercises over 28 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: BTL EMSELLA
Description: High intensity focused electromagnetic (HIFEM) technology induces deep pelvic floor muscle contractions designed to deliver the equivalent of 11,200 Kegel exercises over 28 minutes.
Study: NCT04887376

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mirror frame
Description: Combined Mirror and NMES therapy

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Only NMES therapy
Study: NCT00305929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment with Tookad VTP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment with Tookad VTP
Description: Tookad 2 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment with Tookad VTP
Description: 2 mg/kg
Study: NCT01416597

Intervention type: BIOLOGICAL
Intervention: Vaccines
Description: Unadjuvanted, monovalent, and trivalent vaccines, and vaccines delivered intramuscularly, intradermally, or intranasally, depending on what is found in the included studies.
Study: NCT01261780

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MC-5A
Description: 45 minutes daily x 10 treatments (given over the course of 2 weeks)

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham device
Description: Sham therapy daily x 45 minutes for 10 treatments (given over course of 2 weeks)
Study: NCT03977740

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chest PNF
Description: Chest PNF technique includes oblique downward pressure at sternum, diagonal pressure at lower rib cage at supine line, caudal medial pressure at side lying, Caudal pressure at ribcage at prone lying, dorsal and caudal pressure at prone on elbow.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: conventional chest physiotherapy treatment, which includes Deep breathing exercise, Diaphragmatic breathing exercise, segmental breathing exercise and purse lip breathing and incentive spirometer
Study: NCT03021161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic Formula
Description: The intervention group will receive once daily capsules containing 109 CFU of Lactobacillus rhamnosus HN001, Lactobacillus paracasei Lpc-37 and Bifidobacterium animalis ssp. Lactis HN019

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: Capsule containing no probiotic
Study: NCT03980353

Intervention type: OTHER
Intervention: Questionnaires
Description: The questionnaires have two parts: a general part and a second part focused on the integration in community of the type 1 diabetes children with specific questions about blood glucose, mealtimes, sporting activities and school trips.
Study: NCT04284462

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Flavored carbonated soft drink (CSD)
Description: 1-2 cans/day (330 ml per can)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Flavored carbonated soft drink (CSD)
Description: 1-2 cans/day (330 ml per can)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flavored carbonated soft drink (CSD)
Description: 1-2 cans/day (330 ml per can)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flavored carbonated soft drink (CSD)
Description: 1-2 cans/day (330 ml per can)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flavored carbonated soft drink (CSD)
Description: 1-2 cans/day (330 ml per can)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flavored carbonated soft drink (CSD)
Description: 1-2 cans/day (330 ml per can)
Study: NCT02061527

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reconstruction with ADM.
Description: If the patient wishes to undergo immediate implant based reconstruction, and meets the selection criteria for entering the study, she is randomly selected to be treated according to Group A or Group B. Group A (no intervention) will be reconstructed with expander or anatomical gel implant without ADM, using complete muscle coverage. Group B (Intervention) will be reconstructed with expander or anatomical gel implant using partial muscle coverage in conjunction with ADM.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin or nipple sparing mastectomy
Description: Mastectomy for invasive or pre-invasive breast cancer

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Skin or nipple sparing mastectomy
Description: Mastectomy for invasive or pre-invasive breast cancer

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reconstruction with implant
Description: Immediate breast reconstruction with implant

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reconstruction with implant
Description: Immediate breast reconstruction with implant

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total submuscular coverage
Description: Implant based breast reconstruction with total submuscular coverage

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial submuscular coverage
Description: Implant based breast reconstruction with partial submuscular coverage
Study: NCT03497598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannose
Description: The powder is dispensed in 2g neutral sticks and ready to be dissolved in 100ml of water for daily oral ingestion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose
Description: The powder is dispensed in 2g neutral sticks and ready to be dissolved in 100ml of water for daily oral ingestion.
Study: NCT01116856

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Different groups will carry out different exercise protocols during 16 weeks under the same nutritional intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Different groups will carry out different exercise protocols during 16 weeks under the same nutritional intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Different groups will carry out different exercise protocols during 16 weeks under the same nutritional intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Different groups will carry out different exercise protocols during 16 weeks under the same nutritional intervention.
Study: NCT04303728

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Muscle ultrasound
Description: The muscle thickness and muscle quality will be assessed on ultrasound
Study: NCT04184388

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydrolysed Red Ginseng Extract
Description: once a day for 1 p.o., after breakfast(10 ml/day, Hydrolysed Red Ginseng extract for 1g/day) for 12 week

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once a day for 1 p.o., after breakfast(10 ml/day, Hydrolysed Red Ginseng extract for 0g/day) for 12 week
Study: NCT00307008

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumovax 23™
Description: Single dose intramuscular injection
Study: NCT01381562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: GSK2251052
Description: Reconstituted, added to 250mL 0.9% NaCl solution and administered via IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: GSK2251052
Description: Reconstituted, added to 250mL 0.9% NaCl solution and administered via IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: Reconstituted, added to 100mL 0.9% NaCl solution and administered via IV infusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: saline placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: saline placebo

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: saline placebo
Study: NCT00798278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urokinase
Description: Chest tube with intrapleural urokinase infusion for 3 days

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Video-Assisted Thoracoscopic
Description: Video-Assisted Thoracoscopic decortication
Study: NCT01630278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Very premature infants with a large ductus, selected by an early echocardiogram, will receive ibuprofen before 12 hours of life

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Very premature infants with a large ductus, selected by an early echocardiogram, will receive placebo before 12 hours of life
Study: NCT02572284

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: The first group of patients to enter the study will receive 5 Gy of SBRT per day for 5 days, the second group will receive 6 Gy per day for 5 days. Each treatment will take about 3 minutes and be given as an outpatient at Moffitt Cancer Center.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prostatectomy
Description: About 4-6 weeks after SBRT, participants will have a prostatectomy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Life Questionnaires
Description: Patient assessed health-related quality of life (HRQOL). Quality of Life (QOL) will be assessed using Prostate Symptom Score (IPSS), rectal assessment scale (RAS), sexual health inventory for men (SHIM), and Expanded Prostate Cancer Index Composite (EPIC) patient questionnaires: administered prior to SBRT, and at 2 weeks, 4 weeks, 2 months and then every 3 months up to 18 months post-prostatectomy.
Study: NCT01361841

Intervention type: DRUG
Group type: OTHER
Intervention: Latanoprost, bimatoprost, travoprost
Description: topic drops, once a day at bedtime, for years

Intervention type: DRUG
Group type: OTHER
Intervention: travoprost, latanoprost and bimatoprost
Description: one drop once a day for life
Study: NCT00968422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-384
Description: 3 escalating doses will be administered daily for 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-384
Description: 3 escalating doses will be administered daily for 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-384
Description: 3 escalating doses will be administered daily for 21 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo to ABT-384
Description: Doses will be administered daily for 21 days
Study: NCT00836550

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video
Description: The participants saw a 6 minute video

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: in-person HIV pre-test counseling
Study: NCT03599180

Intervention type: DEVICE
Intervention: microdialysis
Description: Use microdialysis skill to collect dialyzate at sensitization acupoints

Intervention type: DEVICE
Intervention: microdialysis
Description: Use microdialysis skill to collect dialyzate at sensitization acupoints
Study: NCT00826735

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided imagery
Description: A relaxation focused guided imagery intervention was used through the remainder of pregnancy plus a physiologic guided imagery intervention was used during the third stage of labor.
Study: NCT03062254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: radium-223 dichloride
Description: 6 doses of Radium-223